Published in Mol Ther on January 01, 2003
The blood-brain barrier: bottleneck in brain drug development. NeuroRx (2005) 5.45
Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res (2007) 1.54
shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev (2007) 1.42
Drug transport to brain with targeted nanoparticles. NeuroRx (2005) 1.37
Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res (2009) 1.32
Nonviral approaches for neuronal delivery of nucleic acids. Pharm Res (2007) 1.07
Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine (2008) 1.06
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
Drug transport to brain with targeted liposomes. NeuroRx (2005) 1.05
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci (2013) 0.90
Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J Control Release (2007) 0.90
Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx (2005) 0.87
RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx (2005) 0.84
The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier. J Drug Deliv (2011) 0.79
Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics (2015) 0.77
Targeted endothelial nanomedicine for common acute pathological conditions. J Control Release (2015) 0.77
Nanoparticle transport across the blood brain barrier. Tissue Barriers (2016) 0.76
Inhibition of monocyte adhesion to brain-derived endothelial cells by dual functional RNA chimeras. Mol Ther Nucleic Acids (2014) 0.75
Non-viral gene therapy that targets motor neurons in vivo. Front Mol Neurosci (2014) 0.75
Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem (2002) 1.73
Alert for increased long-term follow-up after carotid artery stenting: results of a prospective, randomized, single-center trial of carotid artery stenting vs carotid endarterectomy. J Vasc Surg (2008) 1.60
Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng (2007) 1.44
Intracranial hemorrhage: frequency, location, and risk factors identified in a TeleStroke network. Neuroreport (2015) 1.42
Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng (2007) 1.42
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res (2004) 1.42
Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res (2006) 1.40
Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem (2007) 1.36
Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng (2009) 1.33
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.30
Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther (2005) 1.26
Cerebral ischemia-reperfusion injury in rats--a 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation. J Cereb Blood Flow Metab (2009) 1.23
Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol (2007) 1.20
Synthesis of pegylated immunonanoparticles. Pharm Res (2002) 1.18
Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther (2003) 1.11
GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.10
Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke (2011) 1.09
Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther (2004) 1.09
AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol (2009) 1.09
Transcranial duplex sonography in the detection of patent foramen ovale. Radiology (2002) 1.08
Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther (2002) 1.07
Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos (2009) 1.07
Letter by Schlachetzki et al regarding article, "endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome". Stroke (2013) 1.07
Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res (2007) 1.06
High-dose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol (2003) 1.05
Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med (2002) 1.04
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol (2010) 1.04
In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med (2003) 1.02
Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med (2004) 1.01
Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther (2002) 1.01
Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab (2002) 1.00
Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm (2010) 0.99
Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem (2008) 0.98
Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm (2009) 0.97
Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab (2012) 0.97
Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today (2002) 0.97
Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis (2003) 0.95
Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther (2010) 0.95
The blood-brain barrier and neurotherapeutics. NeuroRx (2005) 0.94
Detection of adiponectin in cerebrospinal fluid in humans. Am J Physiol Endocrinol Metab (2007) 0.94
Genetic engineering of IgG-glucuronidase fusion proteins. J Drug Target (2010) 0.94
Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. J Neurochem (2002) 0.94
Vascular genomics of the human brain. J Cereb Blood Flow Metab (2002) 0.93
Translational science: what is it and why is it so important? Drug Discov Today (2003) 0.93
Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos (2010) 0.93
Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res (2010) 0.92
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm (2009) 0.92
Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. J Neuropathol Exp Neurol (2002) 0.91
P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport (2003) 0.91
Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target (2002) 0.91
Comprehensive small animal imaging strategies on a clinical 3 T dedicated head MR-scanner; adapted methods and sequence protocols in CNS pathologies. PLoS One (2011) 0.91
Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem (2013) 0.90
Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos (2010) 0.90
Recurrent cardiac arrest caused by lateral medulla oblongata infarction. BMJ Case Rep (2009) 0.90
Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci (2002) 0.89
Rat blood-brain barrier genomics. II. J Cereb Blood Flow Metab (2002) 0.89
Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J Nucl Med (2002) 0.88
Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem (2010) 0.88
Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem (2003) 0.88
Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res (2003) 0.88
Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res (2007) 0.88
Blood-brain barrier disruption following the internal carotid arterial perfusion of alkyl glycerols. J Drug Target (2002) 0.88
Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm (2011) 0.88
Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. J Drug Target (2012) 0.87
Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos (2011) 0.87
Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab Dispos (2011) 0.87
Marked enhancement in gene expression by targeting the human insulin receptor. J Gene Med (2003) 0.87
Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm Res (2008) 0.87
Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng (2011) 0.86
Hyperperfusion syndrome after MCA embolectomy - a rare complication? Am J Case Rep (2013) 0.86
The role of ECA transection in the development of masticatory lesions in the MCAO filament model. Exp Neurol (2005) 0.85
Do normal d-dimer levels reliably exclude cerebral sinus thrombosis? A solution of problems? Stroke (2005) 0.85
Blood-brain barrier genomics and cloning of a novel organic anion transporter. J Cereb Blood Flow Metab (2007) 0.85
Neurovascular protection by targeting early blood-brain barrier disruption with neurotrophic factors after ischemia-reperfusion in rats*. J Cereb Blood Flow Metab (2013) 0.85
Isoflurane induces endothelial apoptosis of the post-hypoxic blood-brain barrier in a transdifferentiated human umbilical vein endothelial cell model. PLoS One (2012) 0.85
Brain drug development and brain drug targeting. Pharm Res (2007) 0.85
Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng (2012) 0.85
Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J Gene Med (2008) 0.84
Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem (2003) 0.84
Long-term outcome after hemicraniectomy for space occupying right hemispheric MCA infarction. Clin Neurol Neurosurg (2005) 0.84
Fischer-344 rats are unsuitable for the MCAO filament model due to their cerebrovascular anatomy. J Neurosci Methods (2006) 0.84
Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos (2012) 0.84
IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng (2010) 0.83
Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc (2010) 0.83
Gene therapy of the brain: the trans-vascular approach. Neurology (2004) 0.83
Prehospital stroke diagnosis and treatment in ambulances and helicopters-a concept paper. Am J Emerg Med (2013) 0.83
Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Mol Pharm (2010) 0.83
Vascular proteomics and subtractive antibody expression cloning. Mol Cell Proteomics (2002) 0.83
Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe--results of an open-labeled non randomized phase I/II trial. PLoS One (2011) 0.83
Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Pediatr Res (2004) 0.82
Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med (2004) 0.82
Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J Neurochem (2003) 0.82
Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim Biophys Acta (2005) 0.82
Transcranial ultrasound from diagnosis to early stroke treatment. 1. Feasibility of prehospital cerebrovascular assessment. Cerebrovasc Dis (2008) 0.82